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Abstract
Regulatory T cells (Treg cells) are increased in context of malignancies and their expansion can be correlated with higher
disease burden and decreased survival. Initially, interleukin 2 (IL-2) has been used as T-cell growth factor in clinical
vaccination trials. In murine models, however, a role of IL-2 in development, differentiation, homeostasis, and function of
Treg cells was established. In IL-2 treated cancer patients a further Treg-cell expansion was described, yet, the mechanism of
expansion is still elusive. Here we report that functional Treg cells of a naı ¨ve phenotype - as determined by CCR7 and
CD45RA expression - are significantly expanded in colorectal cancer patients. Treatment of 15 UICC stage IV colorectal
cancer patients with IL-2 in a phase I/II peptide vaccination trial further enlarges the already increased naı ¨ve Treg-cell pool.
Higher frequencies of T-cell receptor excision circles in naı ¨ve Treg cells indicate IL-2 dependent thymic generation of naı ¨ve
Treg cells as a mechanism leading to increased frequencies of Treg cells post IL-2 treatment in cancer patients. This finding
could be confirmed in naı ¨ve murine Treg cells after IL-2 administration. These results point to a more complex regulation of
Treg cells in context of IL-2 administration. Future strategies therefore might aim at combining IL-2 therapy with novel
strategies to circumvent expansion and differentiation of naı ¨ve Treg cells.
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Introduction
Human regulatory T cells (Treg cells) have been characterized as
CD4
+CD25
high T cells with inhibitory function [1]. They are
crucial for the preservation of T-cell homeostasis and self-tolerance
and regulate the immune responses to alloantigens, pathogens and
tumors [2]. Both in humans and animal models activation of Treg
cells results in exertion of their full suppressive function [3,4].
Natural Treg cells are generated in the thymus as a distinct lineage
of anergic CD4
+ T cells bearing self-reactive T-cell receptors,
although cells with similar characteristics can also be generated in
the periphery under appropriate conditions [5]. Typically, Treg
cells express cytotoxic T-lymphocyte–associated-antigen 4 (CTLA-
4) and glucocorticoid-induced tumor-necrosis-factor receptor-
related protein (GITR), although both molecules can also be
expressed by activated T cells [6,7]. The transcription factor
forkhead box P3 (FOXP3) has been demonstrated to be expressed
exclusively on Treg cells in the mouse [2], while data concerning its
expression in humans are not as clear-cut [8,9]. In numerous
murine tumor models increased frequencies of CD4
+CD25
high
Treg cells seem to be a hallmark of tumor progression and
metastasis [10,11]. Moreover, efficient anti-tumor immune
responses are induced by deletion of these cells resulting in
complete tumor regression [12,13]. In humans, we and others
have demonstrated that CD4
+CD25
highFOXP3
+ Treg cells are also
expanded in patients with solid tumors and hematologic
malignancies and contribute to the overall immunosuppression
in these patients [14,15]. Numerous animal models over the last
years could demonstrate that increased numbers of Treg cells are
beneficial for tumor growth while depletion of Treg cells can lead
to tumor regression [16]. In humans, administration of an IL-2
immunotoxin to tumor patients results in decreased numbers of
Treg cells and higher responses against simultaneously adminis-
tered tumor peptides [17,18]. Several studies over the last years
have addressed the question of Treg-cell frequencies in colorectal
cancer patients [19,20,21]. These reports could demonstrate
increased number of FOXP3
+ Treg cells in the peripheral blood,
tumor-draining lymph nodes and in close tumor proximity
[19,20,21]. Still, the question why Treg cells are expanded in
human tumors remains elusive.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30422CD45RO expression has been primarily linked to Treg cells,
which led to the assumption that Treg cells belong to the memory
T-cell compartment [4,22]. Recently, a Treg-cell population with a
naı ¨ve phenotype (CCR7
+CD45RA
+) was identified in healthy
individuals [23,24]. These naı ¨ve Treg cells proliferated vigorously
in response to auto-antigens suggesting that particularly this
subpopulation was specific for self rather than foreign antigens
[23]. Persistence of naı ¨ve Treg cells has been described throughout
adult life [25,26], although it must be pointed out that this pool of
naı ¨ve Treg cells is relatively small in peripheral blood of healthy
individuals [27]. In patients with multiple myeloma (MM),
however, we could demonstrate an expansion of naı ¨ve Treg cells
[28]. We could validate this finding for a number of hematologic
malignancies and patients with solid tumors and even show strong
suppressive function for the naı ¨ve Treg-cell population [29].
Comparison of levels of T-cell receptor excision circles (TREC)
in Treg cells of healthy individuals addressed the diversity and
developmental stage of thymic emigrants as well as peripheral
blood Treg cells [30,31]. As expected, TREC numbers were
significantly higher in thymic emigrants compared to peripheral
blood derived Treg cells, which supports thymic development of
human CD4
+CD25
high Treg cells [31].
On the one hand, IL-2 is both important for the development
and expansion of effector T cells and also critical in the context of
immune tolerance [32]. On the other hand, experiments
performed in murine models established that IL-2 and its
downstream effector molecules are essential for the generation,
maintenance, and function of Treg cells [33,34,35,36]. Several
studies have addressed the role of IL-2 administration on the
frequency and function of human Treg cells in cancer patients and
demonstrated that treatment with recombinant IL-2 induces an
expansion of Treg cells in peripheral blood, thereby interfering
with efficient anti-tumor immune responses [37,38,39,40,41,
42,43]. These studies pointed to a peripheral expansion of Treg
cells post IL-2 therapy [41]. It was further suggested that altered
migratory behavior due to increased expression of CCR4 and
CXCR4 on Treg cells might be associated with peripheral
expansion and increased migration to the tumor site [41]. In
two recent studies however, Correale et al. demonstrated that the
combination of chemotherapy with GM-CSF and IL-2 adminis-
tration leads to reduced Treg-cell numbers [44,45]. These findings
suggested a more complex regulation of Treg-cell frequency,
distribution and function than previously thought. Moreover, it
remains unclear whether different mechanisms might be respon-
sible for frequency changes of Treg cells in these different patient
populations treated with IL-2.
In the current study, we investigated the impact of IL-2
administration on the frequency and function of CD4
+CD25
high-
FOXP3
+ Treg cells. We provide clear evidence for an increased
expansion of naı ¨ve Treg cells particularly post IL-2 therapy as a
major mechanism of overall Treg-cell expansion in these cancer
patients. Our data clearly suggest an increase of newly generated
Treg cells in cancer patients. These novel findings are of particular
interest for strategies targeting Treg cells in cancer patients.
Results
Increased frequencies of CD4
+CD25
highFOXP3
+ Treg cells
in peripheral blood of patients with metastatic colorectal
cancer
Within a clinical phase I/II combined chemoimmunotherapy
trial of patients with metastatic colorectal cancer we assessed
frequencies of FOXP3-expressing CD4
+CD25
high Treg cells in
peripheral blood before initiation of therapy in comparison to
healthy controls (Fig. 1A). The frequency of Treg cells in healthy
donors (n=22, 2.9%61.2%) was comparable to previously
published results (Fig. 1B) [46,47]. In contrast, individuals with
colorectal cancer assessed before initiation of treatment (n=15,
4.7%61.2%, p,0.001) showed significantly increased frequencies
of Treg cells compared to healthy individuals (Fig. 1A and 1B). We
also assessed previously described surface receptors associated with
Treg cells including CTLA4 and GITR on CD4
+CD25
high-
FOXP3
+ T cells in colorectal cancer patients as well as healthy
individuals. As depicted in Figure 1C, we observed comparable
expression of both molecules on Treg cells from healthy donors and
colorectal cancer patients while percentages of CD4
+CD25
high-
FOXP3
+ Treg cells expressing either molecule were significantly
increased in colorectal cancer patients (CTLA4: 3.7%61.2% vs.
1.5%60.6%, p,0.001; GITR: 1.7%60.8% vs. 0.5%60.2%,
p,0.001) (Fig. 1D).
Expansion of CD4
+CD25
highFOXP3
+ Treg cells after
chemoimmunotherapy including low-dose IL-2
administration
Next, we investigated changes in frequency of Treg cells in
respect to IL-2 administration (Fig. 2). From the 15 patients
included in the trial, 12 successfully completed the whole protocol,
while 3 patients were rapidly progressing under therapy and
deceased shortly thereafter. Blood samples from the 12 patients
(P1–12) who completed the whole treatment were taken after
completion of IL-2 treatment following vaccination. For the 3
rapidly progressing patients (P13–15) who were taken off study,
Treg-cell frequencies were assessed at the last time point were
material was available. As depicted for patient P11 in Figure 2A
we observed an expansion of CD4
+CD25
highFOXP3
+ Treg cells in
the majority of patients. When assessing all patients, 11 colorectal
cancer patients had higher frequencies post therapy while 2 (P3,
P15) had lower frequencies at the second time point of analysis and
two other patients (P4, P5) showed similar frequencies at both time
points (Fig. 2B). No feature (laboratory test, treatment or clinical
parameter) we have assessed so far showed an association with
changes in Treg-cell frequency in these patients (data not shown).
In addition, we did not observe any cytopenia greater grade 2
during therapy. Overall, in the majority of patients the frequency
of Treg cells after combined chemoimmunotherapy was increased
compared to the initial frequencies before treatment (5.8%61.7%
vs. 4.7%61.2%, p,0.05) (Fig. 2C) as well as in comparison to
healthy donors (5.8%61.7% vs. 2.9%61.2%, p,0.001). When
assessing the absolute numbers of Treg cells we observed the same
trend; total numbers of Treg cells were increased after chemoim-
munotherapy (after: 29.2610
6/l620.5610
6/l vs. before: 21.36
10
6/l617.1610
6/l, p,0.005) and only one of the rapidly
progressing patients showed reduced numbers of Treg cells
(Fig. 2D).
Among the 15 colorectal cancer patients, 4 patients had
progressive disease at the time of analysis while 11 showed a
response or stable disease. Comparing these two patient cohorts
revealed no significant difference in the proportion of Treg cells,
whereas both patient cohorts showed higher frequencies of Treg
cells compared to healthy controls (data not shown). Next, we
assessed if Treg-cell frequencies were indicative of longer freedom
from treatment failure or overall survival or if these 2 parameters
were linked to the expansion of Treg cells, yet no statistically
significant correlation was detected (data not shown). Our data
indicate that an expansion of CD4
+CD25
highFOXP3
+ Treg cells
occurred in the majority of colorectal cancer patients after IL-2
administration as part of combined chemoimmunotherapy.
IL-2 Induced Naı ¨ve Treg Cell Expansion in CRC
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+CD25
high Treg cells from
colorectal cancer patients
In 4 colorectal cancer patients sufficient numbers of highly
purified CD4
+CD25
high Tregcells(Fig.3AandB)were isolatedfrom
peripheral blood by flow cytometric cell sorting before and after
vaccination to analyze their inhibitory function in comparison to
Treg cells from healthy controls (n=4). Proliferation of allogeneic
conventional CD4
+CD25
2 T cells stimulated by beads coated with
CD3 and CD28 mAbs was used as the read out to assess inhibitory
functionofCD4
+CD25
highTregcells[28].Proliferationofallogeneic
conventional CD4
+CD25
2 T cells was significantly inhibited when
highly purified CD4
+CD25
high T cells from healthy donors were
added at a 1:1 ratio (white bar, Fig. 3C, p,0.001). On a cell-to-cell
basis highly purified CD4
+CD25
high Treg cells from colorectal
cancer patients (before initiation of therapy) showed an equally
strong inhibitory function on conventional CD4
+CD25
2 T-cell
proliferation (dark grey bar, Fig. 3C, p,0.001). Titration
experiments demonstrated that the inhibitory function of Treg cells
from healthy individuals and colorectal cancer patients was
comparable also at lower Treg:Tconv ratios (data not shown).
Moreover, after IL-2 treatment of colorectal cancer patients (after
treatment), Treg cells had equal suppressive function on conven-
tional CD4
+CD25
2 T-cell proliferation when compared to Treg
cells isolated before start of therapy (light grey bar, Fig. 3C,
p,0.001). Taken together, these data suggest, that Treg cells from
colorectal cancer patients have normal suppressive function.
Figure 1. Frequency of CD4
+CD25
highFOXP3
+ Treg cells. (A) Flow cytometric analysis of CD25 and FOXP3 on peripheral blood derived CD4
+ T
cells from a representative healthy individual (left panel) and a representative colorectal cancer patient before treatment (right panel). Numbers
represent percentage of events within the gate. (B) Frequency of CD4
+CD25
highFOXP3
+ Treg cells in 22 healthy donors and 15 colorectal cancer
patients (CRC) before treatment. Each dot represents a single individual assessed in the respective group; mean expression (line) of all samples in
each group is also shown (*, p,0.05, Student’s t test). (C) CTLA4 (top) and GITR expression (bottom) in CD4
+CD25
highFOXP3
+ Treg cells of healthy
donors (left, grey fill) and colorectal cancer patients (right, grey fill). Isotype control (black line). (D) Frequency of CTLA4 (left) and GITR (right)
expressing CD4
+CD25
highFOXP3
+ Treg cells in healthy donors (white) and colorectal cancer patients (grey, CRC) before treatment. Shown here are
median, 25
th and 75
th percentile (box), 10
th and 90
th percentile (whiskers) and outliers (dots), (*, p,0.05, Student’s t test).
doi:10.1371/journal.pone.0030422.g001
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+CD25
highFOXP3
+ Treg cells after chemoimmunotherapy. (A) Flow cytometric analysis of CD25
and FOXP3 on peripheral blood derived CD4
+ T cells from a representative colorectal cancer patient before (left panel) and after
chemoimmunotherapy (right panel). Numbers represent percentage of events within the gate. (B) Serial analysis of frequencies of
CD4
+CD25
highFOXP3
+ Treg cells in colorectal cancer patients before and after chemoimmunotherapy. (C) Frequency of CD4
+CD25
highFOXP3
+ Treg
cells in 15 colorectal cancer patients before (light grey box) and after (dark grey box) chemoimmunotherapy. Shown here are median, 25
th and 75
th
percentile (box), 10
th and 90
th percentile (whiskers) and outliers (dots), (*, p,0.05, Student’s t test). (D) Serial analysis of total numbers of
CD4
+CD25
highFOXP3
+ Treg cells in colorectal cancer patients before and after chemoimmunotherapy.
doi:10.1371/journal.pone.0030422.g002
Figure 3. Functional analysis of CD4
+CD25
highFOXP
+ Treg cells. (A) CD4
+ cells were separated by flow cytometric cell sorting into
conventional CD4
+CD25
2 and regulatory CD4
+CD25
high T cells as defined by their expression of CD25. (B) Re-analysis of FOXP3 expression in
CD4
+CD25
2 Tconv (left, grey fill) and CD4
+CD25
high Treg cells (right, grey fill) post cell sorting. Isotype control (black line). (C) Reduction of proliferation
of CD4
+CD25
2 Tconv cells stimulated with beads coated with CD3 and CD28 mAbs (black bar) by highly purified CD4
+CD25
highFOXP3
+ Treg cells from
healthy donors (white bar) or colorectal cancer patients before (dark grey bar) and after therapy (light grey bar).
doi:10.1371/journal.pone.0030422.g003
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cancer patients after chemoimmunotherapy
It has been previously reported by us and others that differential
expression of the cell surface receptors CD45RA and CCR7 can
be used to differentiate between naı ¨ve, central and effector
memory Treg cells (Fig. 4A) [23,28,48]. This approach can be used
to address the question, if naı ¨ve, central or effector memory Treg
cells contribute to the overall expansion of Treg cells in patients
with solid tumors and how treatment, particularly administration
of IL-2 influences the frequency and function of naı ¨ve versus
memory CD4
+CD25
highFOXP3
+ Treg cells. In healthy individuals,
naı ¨ve CCR7
+CD45RA
+ Treg cells were hardly detectable (Fig. 4B).
Treg cells were almost exclusively of a memory phenotype (Fig. 4C
and D) with a higher frequency of TEM cells (Fig. 4D). In contrast,
in colorectal cancer patients we observed a significantly higher
number of Treg cells with a CCR7
+CD45RA
+ naı ¨ve phenotype
(Fig. 4B). This was further accompanied by an increase of Treg
cells with a central memory phenotype in colorectal cancer
patients prior to therapy (Fig. 4C) while effector memory Treg cell
levels were comparable in colorectal cancer patients (prior to
therapy) and healthy donors (Fig. 4D). However, most surprising,
after IL-2 treatment, expansion of Treg cells almost exclusively
occurred within the naı ¨ve Treg-cell population (Fig. 4B) while
frequencies of central and effector memory Treg cells remained
unchanged (Fig. 4C and D). To further characterize the increased
subset of naı ¨ve CD4
+CD25
highFOXP3
+ Treg cells, we assessed the
expression of intracellular CTLA4 or GITR expression. Compa-
rable to the data obtained for the total Treg-cell population both
molecules were expressed at similar levels on a per cell basis on
naı ¨ve Treg-cells from healthy individuals and cancer patients
irrespective of IL-2 treatment (data not shown) while percentages
of CD4
+CD25
highFOXP3
+ Treg cells expressing either molecule
were significantly increased in colorectal cancer patients (CTLA4:
0.31%60.23% vs. 0.05%60.01%, p,0.05; GITR: 0.10%6
0.07% vs. 0.02%60.01%, p,0.05) with a further increase after
IL-2 administration (CTLA4: 0.78%60.56% vs. 0.31%60.23%,
p,0.001; GITR: 0.24%60.19% vs. 0.10%60.07%, p,0.05)
(Fig. S1).
Next, we assessed the suppressive function of naı ¨ve versus
memory Treg-cell populations before and after therapy (Fig. 4E).
We observed a clear inhibition of conventional CD4
+CD25
2 T-
cell proliferation induced by stimulation with CD3/CD28-coated
beads by adding sorted Treg cells to the culture irrespective of the
subtype (naı ¨ve vs. memory) used or the status of therapy (no
therapy vs. chemoimmunotherapy) demonstrating that the differ-
ent subtypes of Treg cells have full suppressive activity independent
of IL-2 therapy. Taken together, these data demonstrate a
significant expansion of naı ¨ve Treg cells post IL-2 treatment.
Furthermore, these cells are similarly effective in suppressing
conventional T-cell activation when analyzed on a cell-to-cell
basis, suggesting an overall higher suppressive effect of these cells
in colorectal cancer patients.
Thymic expansion of naı ¨ve CD4
+CD25
highFOXP3
+ Treg
cells in patients with colorectal cancer after IL-2
administration
As Treg cells with a naı ¨ve phenotype were increased in patients
with colorectal cancer, particularly post IL-2 treatment, we were
interested to assess whether the increase of Treg cells resulted from
peripheral expansion or possibly thymic generation of
CD4
+CD25
highFOXP3
+ Treg cells. We previously reported that
the level of TREC can be used as a marker to estimate the
developmental vicinity of Treg cells to the thymus and their
division history [28] and therefore applied TREC analysis to
address this issue in relation to IL-2 treatment. PB derived CD4
+
T cells from two colorectal cancer patients and two age-matched
healthy individuals were sorted according to their CD25, CCR7
and CD45RA expression into the appropriate CD4
+CD25
high
Treg-cell subsets, namely Tnaı ¨ve,T CM, and TEM (Fig. 5A and B).
TREC values for the highly purified Treg-cell subsets were assayed
by real-time PCR. As described before, CD4
+CD25
high Treg cells
showed relatively low TREC contents in the naı ¨ve T-cell
population and TREC levels were below detection threshold in
the TCM and TEM subsets (Fig. 5C) [28]. These observations are in
line with the concept of antigen-driven peripheral expansion of
Treg cells in healthy individuals rather than recent thymic
emigration. In contrast, the TREC content on the single cell level
in naı ¨ve CD4
+CD25
high Treg cells in colorectal cancer patients was
more than two-fold higher in average compared to healthy
individuals before initiation of chemoimmunotherapy and even
more increased after administration of IL-2 (.4–fold in average,
Fig. 5C). These results strongly suggest that the expansion of Treg
cells in colorectal cancer patients was nurtured by the generation
of new Treg cells in the thymus and the further increase of Treg-cell
frequencies post IL-2 administration was strongly associated with
an increase of thymic emigrants of naı ¨ve Treg cells.
Administration of IL-2 leads to an expansion of a
population of murine ‘‘naı ¨ve’’ CD4
+ CD25
highFOXP3
+ Treg
cells
To demonstrate that IL-2 administration indeed leads to an
increase of naı ¨ve Treg cells, we administered IL-2 or PBS i.p. in
C57BL/6 mice for 10 days and assessed the frequency of
CD4
+CD25
highFOXP3
+ Treg cells in these animals after the
treatment period. In comparison to PBS-treated animals a
significant expansion of CD4
+CD25
highFOXP3
+ Treg cells oc-
curred after IL-2 administration in spleen, peripheral as well as
mesenteric lymph nodes, peripheral blood, thymus, and liver
(Fig. 6A). Of particular interest was the increase of Treg cells in the
thymus, which could be indicative of an increased thymic output.
As a first approximation for vicinity of T cells to thymic output
expression of CD45RB on CD4
+CD25
highFOXP3
+ Treg cells was
assessed since up to now no true marker for murine naı ¨ve Treg cells
has been established. We observed a significant increase of
CD45RB
high CD4
+CD25
highFOXP3
+ Treg cells in spleen, periph-
eral as well as mesenteric lymph nodes, peripheral blood, thymus,
and liver of IL-2 treated mice (Fig. 6B) clearly indicating that an
increase of naı ¨ve Treg cells contributed to the overall expansion of
Treg cells after IL-2 administration and that the overall Treg-cell
expansion was related to elevated frequencies of naı ¨ve Treg cells in
the thymus.
To further delineate if IL-2 treatment induces generation of
naı ¨ve Treg cells in the thymus we sorted CD45RB
+
CD44
lowCD62L
+ naı ¨ve Tconv and Treg cells from IL-2 as well as
PBS treated animals (Fig. 6C) and assessed TREC levels in the
naı ¨ve Tconv and Treg-cell population. We observed significantly
higher levels of TREC in Tconv and Treg-cell populations after IL-2
administration (Fig. 6C) suggesting that IL-2 treatment indeed
results in a higher thymic output of naı ¨ve Treg cells as observed in
IL-2 treated human colorectal cancer patients.
Discussion
In the current study we addressed the question whether IL-2
treatment leads to an expansion of fully functional Treg cells in
colorectal cancer patients and whether an increase of Treg cells in
colorectal cancer patients is due to peripheral or thymic
IL-2 Induced Naı ¨ve Treg Cell Expansion in CRC
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30422expansion. Using phenotypic, functional and molecular approach-
es we demonstrate an increase of CD4
+CD25
highFOXP3
+ Treg
cells in colorectal cancer patients already before initiation of an IL-
2 containing chemoimmunotherapy regimen. The increase of Treg
cells in these patients was further augmented after completion of
treatment, clearly demonstrating that IL-2 treatment is associated
with an increase in Treg-cell numbers an alarming effect which
could potentially influence and dampen the immune response in
an immunotherapy protocol. Treg cells expressed phenotypic
markers associated with Treg cells (e.g. CTLA-4 and GITR) and
suppressed the proliferation of CD4
+CD25
2 Tconv cells. Further-
more, we can clearly show that Treg cells in colorectal cancer
patients have normal suppressive function.
In addition, we demonstrate that the expansion of Treg cells in
colorectal cancer patients was particularly prominent within the
naı ¨ve CCR7
+CD45RA
+ CD4
+CD25
highFOXP3
+ Treg cell popu-
lation and to a lesser extent in central memory Treg cells, while
there was no difference in Treg cells with an effector memory
phenotype. Most surprising, expansion of Treg cells post IL-2
treatment was almost exclusively due to an increase of naı ¨ve Treg
cells. Expansion of naı ¨ve Treg cells was further supported by the
increase of TREC numbers that were significantly higher in naı ¨ve
Treg cells from untreated colorectal cancer patients when
compared to healthy controls and further increased post IL-2
treatment. To demonstrate that the observed results in humans are
dependent on the IL-2 administration, we treated mice with IL-2
and could detect increased levels of Treg cells in these animals. In
line with our results in humans, we observed thymic generation of
naı ¨ve Treg cells after IL-2 treatment as shown by high TREC levels
in the naı ¨ve Treg-cell population. These findings strongly suggest
that Treg-cell expansion in colorectal cancer patients is due to
higher thymic output which is further increased by IL-2 treatment.
Over the last years several murine studies showed the
importance of IL-2 for Treg cells. IL-2 is a critical growth factor
Figure 4. Increase of naı ¨ve CD4
+CD25
highFOXP3
+ Treg cells in colorectal cancer patients after chemoimmunotherapy. (A) Strategy of
flow cytometric analysis of CCR7 and CD45RA expression on the surface of CD4
+CD25
highFOXP3
+ Treg cells as exemplified for a representative healthy
donor (left) and a representative colorectal cancer patient (right). Frequencies of (B) CCR7
+CD45RA
+ naı ¨ve Treg cells (Tnaive), (C) CCR7
+CD45RA
2
central memory Treg cells (TCM), and (D) CCR7
2CD45RA
2 effector memory Treg cells (TEM) were assessed in peripheral blood of colorectal cancer
patients (n=15) before (light grey bars) and after therapy (dark grey bars) as well as healthy individuals (white bars, n=22). Significant differences
(p,0.05, Student’s t test) between healthy donors and colorectal cancer patients before and after chemoimmunotherapy are marked by an asterisk
(*). Error bars represent SD. (E) Assessment of regulatory function of naı ¨ve and memory CD4
+CD25
high Treg cells sorted according to their CD45RA
expression from colorectal cancer patients. Reduction of proliferation of CD4
+CD25
2 Tconv cells stimulated with beads coated with CD3 and CD28
mAbs by highly purified naı ¨ve and memory CD4
+CD25
high Treg cells from colorectal cancer patients before and after therapy.
doi:10.1371/journal.pone.0030422.g004
IL-2 Induced Naı ¨ve Treg Cell Expansion in CRC
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regulation of Treg cells in the periphery [33,34,35]. IL-2 seems to
be involved in the generation of Treg cells during antigen-specific
immune responses [49] and has been suggested to be involved in
the suppressive function of Treg cells [50,51]. In human Treg-cell
biology, IL-2 is supposed to induce a peripheral expansion of
CD4
+CD25
highFOXP3
+ Treg cells as suggested by Wei et al. [41]
while it has no effect on FOXP3 expression in conventional T
cells. This has been further confirmed in a second study which
reported that IL-2 induced STAT-dependent mechanisms are
responsible for the selective expression of FOXP3 in Treg cells and
in vivo expansion following IL-2 administration indicating a unique
programming of CD4
+CD25
high Treg cells within the IL-2
signaling pathway [52].
Most recently increased frequencies of CD4
+CD25
highFOXP3
+Treg
cells were reported for patients with renal cell carcinoma, malignant
melanoma or ovarian cancer patients after IL-2 monotherapy
[37,39,40,41] and administration of IL-2 during immune reconstitu-
tion after chemotherapy in pediatric sarcomas led to a preferential
expansion of Treg cells after cytoreductive chemptherapy [38]. In
contrast, patients with metastatic colorectal cancer treated with a
combined chemoimmunotherapy containing gemcitabine and FOL-
FOX-4 (oxaliplatin, fluorouracil, and folinic acid) polychemotherapy
followed by the subcutaneous administration of GM-CSF and low-
dose IL-2 showed clinical objective responses in the majority of patients
associated with a significant reduction in CD4
+CD25
highFOXP3
+ Treg
cells as reported by Correale et al. [44,45].
Our data however support an alternative outcome of combined
chemoimmunotherapy as low-dose IL-2 in combination with a
peptide-vaccination resulted in increased frequencies of
CD4
+CD25
highFOXP3
+ Treg cells, particularly naı ¨ve Treg cells.
These rather opposite results might be explained by the
differences in the vaccination and chemotherapy protocols, e.g.
high-dose vs. low-dose 5-FU, irinotecan vs. oxaliplatin, forgoing of
gemcitabine, dosage and schedule of GM-CSF administration, or
addition of CAP-1-peptide, in the time course of administration, in
the patient cohort under study (metastatic colorectal cancer vs.
unselected colorectal cancer), number of patients analyzed, and
additional, yet unknown, confounding factors. Further conflicting
might be technical issues as it has been previously stated by
Baecher-Allan et al. that the assessment of human Treg cells is still
difficult and the use of different assays sometimes makes it difficult
to compare different studies [47]. Indeed, a recent study in
patients with renal cell carcinoma or malignant melanoma
suggested an enormously high proportion of naı ¨ve Treg cells
[39]. However, the number of naı ¨ve Treg cells in the healthy
control group was also reported to exceed 50% of all Treg cells, a
frequency that could never be confirmed by us and others [24,27].
Irrespective of these experimental differences in earlier studies,
we clearly unraveled the expansion of naı ¨ve Treg cells to be one of
the mechanisms leading to an overall expansion of fully functional
Treg cells in colorectal cancer patients which was further
augmented by IL-2 therapy. Over the last years differentiation
of Treg cells into naı ¨ve, central and effector memory Treg cells
according to their expression of CCR7 and CD45RA has been
established for healthy individuals [23,24,25,31,53]. We have
incorporated this strategy for the analysis of Treg cells in cancer
patients and demonstrated an expansion of naı ¨ve Treg cells in
human multiple myeloma patients and B-CLL patients [28].
Remarkably, in B cell malignancies, increase of Treg cells was
associated with peripheral expansion of naı ¨ve Treg cells while in
patients with colorectal cancer the expansion seems to be thymus
Figure 5. Replicative history of CD4
+CD25
highFOXP3
+ Treg cell populations defined by the expression of CD45RA and CCR7.
CD4
+CD25
high Treg cells were isolated by flow cytometric cell sorting according to their expression of CD25 as well as CD45RA and CCR7 in three Treg-
cell subsets, namely Tnaı ¨ve (CD45RA
+CCR7
+), TCM (CD45RA
2CCR7
+), and TEM cells (CD45RA
2CCR7
2). (A) Strategy of flow cytometric analysis of CD4
and CD25 expression on the surface of CD4
+ T cells as exemplified for a colorectal cancer patient. (B) Re-analysis of FOXP3 and CD25 expression (left)
as well as CCR7 and CD45RA expression (right) in CD4
+CD25
high Treg cells. (C) Naı ¨ve, central and effector memory CD4
+CD25
high Treg cells from healthy
donors and colorectal cancer patients before and after chemoimmunotherapy were assessed for TREC (T-cell receptor excision circle) content.
Genomic DNA of sorted subsets was isolated, and the number of TREC was determined by quantitative real-time PCR. Data are shown as the mean
values obtained for 2 independent healthy donors and 2 colorectal cancer patients. Error bars represent SD.
doi:10.1371/journal.pone.0030422.g005
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+CD25
highFOXP3
+ Treg cells in C57BL/6 mice. (A) Flow cytometric
analysis of CD4 and FOXP3 expression in CD4
+ T cells from untreated as well as IL-2-treated animals in spleen, peripheral and mesenteric lymph
nodes, peripheral blood, thymus, and liver. Significant differences (p,0.05, Student’s t test) between untreated and IL-2 treated animals are marked
by an asterisk (*). (B) Analysis of ‘‘naı ¨ve’’ CD45RB
high CD4
+CD25
highFOXP3
+ Treg cells in spleen, peripheral and mesenteric lymph nodes, peripheral
blood, thymus, and liver. Significant differences (p,0.05, Student’s t test) between untreated and IL-2 treated animals are marked by an asterisk (*).
Similar results were obtained in two independent experiments. (C) CD45RB
+CD44
lowCD62L
+ naı ¨ve CD4
+CD25
2 Tconv and CD4
+CD25
high Treg cells were
isolated by flow cytometric cell sorting and assessed for TREC content. Genomic DNA of sorted subsets was isolated, and the number of TREC was
determined by quantitative real-time PCR (n=3, p,0.05, Student’s t test). Error bars represent SD. Similar results were obtained in three independent
experiments.
doi:10.1371/journal.pone.0030422.g006
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tion of adjacency of Treg cells to the thymus. Moreover,
administration of IL-2 further augmented this increase. Two
recent publications underlined the importance of IL-2 for the
development of Treg cells in the thymus [54,55], while other results
support a more restricted role for IL-2 of regulating Treg cells in
the periphery without alteration of the thymic output [34]. The
latter proposition has been further strengthened by data obtained
by Wei et al. who could demonstrate expansion of memory Treg
cells in vitro by IL-2 treatment [41]. To address whether effects
induced by IL-2 were limited to peripheral expansion of mainly
memory Treg cells, we treated C57BL/6 mice with IL-2 and
assessed the frequencies of Treg cells with a special focus on naı ¨ve
Treg cells in the periphery and in the thymus. We observed an
overall expansion of Treg cells in these animals and detected a
particular enrichment of naı ¨ve Treg cells in the thymus and
peripheral lymph nodes. By assessment of TREC in the naı ¨ve Treg-
cell population we could demonstrate thymic generation of naı ¨ve
Treg cells as a result of IL-2 adminstration, clearly suggesting that
increased thymic output is an important mechanism leading to
increased frequencies of naı ¨ve Treg cells post IL-2 treatment and
these cells subsequently can differentiate into peripheral Treg cells
with a memory phenotype. Whether peripheral expansion might
also occur under these conditions might be further studied by
administration of IL-2 to thymectomized animals.
The assessment of the source of expanded Treg cells in cancer
patients is of particular importance as the mechanism of
expansion, an augmented production of Treg cells in the thymus,
expansion of Treg cells in the periphery, preferential migration of
Treg cells to the tumor site, increased conversion of conventional T
cells into Treg cells as well as diminished apoptosis and cell death of
peripheral Treg cells, might influence the strategy to therapeuti-
cally target Treg cells to increase anti-tumor immunity. E.g.
peripherally expanded Treg cells might be deleted by short-term
use of cytotoxic agents such as denileukin diftitox while continuing
thymic expansion would require either long-term treatment or
deletion of the cause of thymic expansion of these inhibitory cells
to induce a long-lasting reduction of Treg cells. Other mechanisms
such as conversion of differentiated conventional T cells into Treg
cells might also contribute to the overall expansion of Treg cells in
cancer patients as well the preferential egress of activated Treg cell
from the tumor microenvironment into the peripheral blood and
will have to be addressed when targeting Treg cells [5].
Taken together, we demonstrate an in vivo expansion of fully
functional CD4
+CD25
highFOXP3
+ Treg cells in colorectal cancer
patients due to an increase in naı ¨ve Treg cells with an increased
TREC content. Moreover, naı ¨ve Treg cells with a further increase of
TREC are expanded post IL-2 treatment clearly pointing to an
increased thymic output of naı ¨ve Treg cells after IL-2 therapy, a
mechanism also observed in mice in vivo post IL-2 treatment. This
expansion of Treg cells post administration of IL-2 can potentially
hinder an immune response towards co-administered anti-tumor
reagents and should therefore be avoided when planning new
cancer immunotherapy protocols. The existence of different
mechanisms of expansion of Treg cells (thymic vs. peripheral
expansionandconversion)highlights the complexityofregulationof
these cells and cautions the use of simple strategies targeting these
highly regulated cells in future cancer immunotherapy approaches.
Materials and Methods
Patients and clinical parameters
15 HLA-A2
+ patients with primary metastatic colorectal cancer
were enrolled in this Phase I/II combined chemoimmunotherapy
with a HLA-A2 peptide derived from the carcinoembryonic
antigen CEA (CAP-1) and irinotecan, 5-fluorouracil, and leucov-
orin after approval by the institutional review committee at the
University of Cologne and the German Drug Administration [56].
All patients signed informed consent. Mean age was 56.2613.1
years; 8 were male and 7 were female; 12 had colon while 3 had
rectal cancer. Mean age for the corresponding healthy controls
was 49.569.3 years with no significant differences in gender and
age. Inclusion criteria required an age of between 18 and 75 years,
positive HLA-A2 status, elevated serum CEA (.5 mg/l) and/or
CEA-positive tumor, untreated metastatic disease, chemotherapy-
free interval after adjuvant treatment of at least 6 months,
Karnofsky index .70%, life expectancy of at least 3 months,
sufficient bone marrow and liver function, HIV and hepatitis B
and C negativity, absence of central nervous system metastases, no
immunosuppressant medication, and negative pregnancy test. All
patients received low-dose IL-2 (1610
6 IU) post vaccination. For
vaccination, several approaches were compared in this study,
namely a vaccine containing only the CAP-1-peptide, or the CAP-
1-peptide together with 50 mg GM-CSF (Novartis) or the CAP-1-
peptide together with an oligonucleotide adjuvant (dSLIM,
Mologen); as a fourth option, patients obtained autologous CAP-
1-pulsed dendritic cells as a cellular vaccine. For the analysis of
Treg-cell frequency and function post IL-2 treatment, no
statistically significant influence of the different types of vaccina-
tions could be established (data not shown). Two cycles of
vaccination and IL-2 treatment were given 2 and 1 week before
the first cycle of chemotherapy consisting of 80 mg/m
2 irinotecan,
2,000 mg/m
2 high-dose 5-FU, and 500 mg/m
2 leucovorin (six
weekly administrations). Alternating, two cycles of IL-2 and
vaccination were combined with one cycle of chemotherapy and
repeated three times. After the third cycle, patients were treated
with IL-2 and CAP-1-peptide vaccination on a weekly schedule
until progressive disease. At baseline and after three cycles of
chemoimmunotherapy, patients underwent a leukapheresis to
obtain PBMC for diagnostic and therapeutic purposes. PBMC
were isolated using Ficoll/Hypaque (Amersham, Uppsala, Swe-
den) density centrifugation. Staging was performed according to
the UICC classification for colorectal cancer. All patients were
UICC stage IV. The treatment schedule is provided as Figure S2.
Characteristics of the patients studied are summarized in Table 1.
Antibodies and FACS analysis
Phenotype of T cells was defined by flow cytometry using the
following antibodies: CD4-FITC, CD45RA-PE-Cy-5, CD4-APC,
CD4-APC-Cy-7 (all from Becton Dickinson PharMingen), CD25-
PE-Cy7 (BDBiosciences), CCR7-FITC (R&D Systems) as well as
the corresponding isotype control antibodies (BDPharMingen).
Intracellular staining was performed with the following antibodies:
FOXP3-PE or APC (eBioscience), GITR-FITC (R&D Systems),
CTLA4-PE or with the appropriate isotype controls (BDPharMin-
gen) [28,46]. Cells were stained according to the manufacturer’s
recommendations.
Samples were acquired on a FACSCanto and analyzed with
FlowJo software (TreeStar Inc.). Frequencies of CD4
+CD25
high-
FOXP3
+ T cells are shown as percent values of CD4
+ T cells.
Isolation of CD4
+CD25
high and CD4
+CD25
2 T cells
For functional analysis, CD4
+CD25
high T cells were purified
from PBMC. Briefly, CD4 MACS Beads (Miltenyi Biotec) were
used for isolation of CD4
+ T cells [28,46]. After staining with
CD25-PE, and CD4-APC (BDPharMingen) according to the
manufacturer’s recommendations, CD4
+CD25
high T cells were
purified using a FACSDiVa Cell Sorter (BDBiosciences) and used
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+CD25
2 T cells isolated
from healthy individuals were used as effectors to assess Treg cell
function independently of potential defects of conventional CD4
+
T cells from colorectal cancer patients [28,46]. The cells were re-
analyzed for FOXP3 expression after sorting and routinely showed
.95% purity.
Assessment of inhibitory function
To assess the suppressive activity of Treg cells, 5,6-Carboxy-
fluorescin-Diacetat-Succinimidyl-Ester (CFSE, Sigma-Aldrich)
stained CD4
+CD25
2 T cells (5610
4/well) were stimulated with
magnetic beads (Dynal Biotech) coated with 5% anti-CD3
(OKT3), 14% anti-CD28 (9.3) and 81% anti-MHC class I (W6/
32) at a ratio of 3:1 (cells:beads) in X-VIVO 15 supplemented with
10% fetal calf serum, 100 U/ml penicillin/streptomycin and
2 mM glutamine (all from Invitrogen). PKH-26 (Sigma-Aldrich)-
labelled allogeneic CD4
+CD25
high T cells or naive or memory
CD4
+CD25
high T cells activated for 20 hours with 10 U/ml IL-2
(ProleukinH, Chiron) and 0.5 mg/ml anti-CD3 mAb in X-VIVO
15 (BioWhittakker) were added at a 1:1 ratio to the culture and
proliferation of CD4
+CD25
2 T cells was determined by assessing
CFSE dilution after four days of culture [28].
Isolation of CD4
+CD25
high T-cell subpopulations for
assessment of T-cell receptor excision circles and
functional characterization
Briefly, CD4 MACS Beads were used for isolation of CD4
+ T
cells [46]. After staining with CCR7-FITC, CD25-PE, CD45RA-
PE-Cy-5, and CD4-APC, CD4
+CD25
high T cells and the
respective T cell subsets, CCR7
+CD45RA
+ Tnaı ¨ve, CCR7
+
CD45RA
2 TCM, and CCR7
2CD45RA
2 TEM cells were purified
using a FACSDiVa Cell Sorter and used for either functional
characterization or assessment of TREC levels.
DNA was isolated from purified CD4
+CD25
2, CD4
+CD25
low
and CD4
+CD25
high Tnaı ¨ve,T CM, and TEM cells respectively using
a DNA Isolation Kit (Roche Diagnostics) following the manufac-
turer’s instructions.
Relative TREC levels were determined using real-time PCRwith
a LightCycler (Roche Diagnostics) based on specific primers and
general fluorescence detection with SYBR Green. All PCR were
performedusingLightCycler-FastStartDNAMaster SYBR Green I
kit (Roche Diagnostics). All samples were studied in duplicate
reactions using the human TREC primer kit (Search-LC). The
number of TREC molecules in the sample was calculated as
number of copies per 10
4 cells (detection limit $10 molecules).
Analysis of IL-2 effects on murine Treg cells
Female C57BL/6 mice of 7 weeks were obtained from Elevage
Janvier (France) and maintained in our animal facility. In vivo
experiments were approved by the Animal Care Commission of
Nord-Rhein-Westfalia, Germany (TVZ 9.93.2.10.31.07.089). Af-
ter either treatment with human IL-2 (1610
5 IU/mouse/day,
Proleukin) i.p. or PBS as control for 10 days [57], mice were
sacrificed and their spleens, thymi, liver, and LN removed. Single-
cell suspensions were prepared and stained for flow cytometric
analysis. Antibodies used for staining were CD4-PE-Cy7, CD8a-
Pacific Blue, CD45RB-APC-Cy7, CD25-Alexa 647, and FOXP3-
Alexa 488 as well as appropriate isotype controls (all from
BDBiosciences or BioLegend). Samples were acquired on a
FACSCantoII and analyzed with FlowJo software. Frequencies
of CD4
+CD25
highFOXP3
+ Treg cells are shown as percent values
of CD4
+ T cells.
Table 1. patient characteristics.
Patient ID Sex Age(y)
Primary
tumor
Sites of
metastases Primary vaccine Boost
time point of
2nd analysis
Clinical
response
FFTF
(mo)
Survival
(mo)
P01 M 66 Colon Liver CAP-1+GM-CSF+IL-2 CAP-1+IL-2 after 3 cycles PR 15 34
P02 F 44 Colon Liver CAP-1+dSLIM+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles SD 5 21
P03 F 70 Colon Liver CAP-1+dSLIM+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles SD 12 32
P04 F 32 Colon Liver, spleen,
ovaries, pelvis,
peritoneum
DC-CAP-1+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles CR 12 26
P05 F 60 Colon Liver CAP-1+IL-2 CAP-1+IL-2 after 3 cycles SD 11 15
P06 M 57 Rectum Lung CAP-1+dSLIM+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles SD 7 17
P07 M 44 Rectum Liver CAP-1+dSLIM+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles CR 12 28
P08 M 64 Colon Liver, lung DC-CAP-1+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles SD 10 28
P09 F 43 Rectum Liver, bone,
pararectal,
paraaortal
lymphnodes
CAP-1+GM-CSF+IL-2 CAP-1+GM-CSF+IL-2 after 3 cycles PD 6 13
P10 M 61 Colon Liver CAP-1+dSLIM+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles CR 9 11
P11 M 62 Colon Peritoneum CAP-1+IL-2 CAP-1+IL-2 after 3 cycles CR 13 21
P12 M 55 Colon Liver (primary
resection)
CAP-1+dSLIM+IL-2 CAP-1+dSLIM+IL-2 after 3 cycles CR 24 24
P13 F 38 Colon Liver DC-CAP-1+IL-2 CAP-1+dSLIM+IL-2 after 1 cycle PD 3 10
P14 F 72 Colon Liver, spleen,
lung,
mediastinum
CAP-1+IL-2 CAP-1+IL-2 after 0.5 cycle PD 2 2
P15 M 75 Colon Liver CAP-1+IL-2 CAP-1+IL-2 after 0.5 cycle PD 1 6
doi:10.1371/journal.pone.0030422.t001
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+CD45RB
+CD44
lowCD62L
+ naı ¨ve murine
T-cells for assessment of T-cell receptor excision circles
Briefly, CD4 MACS Beads were used for isolation of murine
CD4
+ T cells from the spleen after treatment with IL-2 as
described above [46]. After staining with CD44-FITC, CD62L-
PE, CD25-Alexa 647, CD45RB-APC-Cy-7, CD8a-PE-Cy-7, and
CD4-Alexa 405, naı ¨ve CD45RB
+CD44
lowCD62L
+ conventional
CD4
+CD25
2 T cells as well as naı ¨ve CD4
+CD25
+ Treg cells were
purified using a FACSDiVa Cell Sorter and used for assessment of
TREC levels.
Murine dRec-yJa TRECs were determined using real-time
quantitative polymerase chain reaction (PCR) as described before
[58]. Briefly, cells were centrifuged and the pellet frozen at 280uC
until analysis. DNA was isolated from purified naı ¨ve CD4
+CD25
2
Tconv and naı ¨ve CD4
+CD25
high Treg cells using a DNA Isolation
Kit (Roche Diagnostics) following the manufacturer’s instructions.
Relative TREC levels were determined using real-time PCR
containing mdRec primer (59-GGGCACACAGCAGCTGTG),
yJa primer (59-GCAGGTTTTTGTAAAGGTGCTCA), and
mdRec-yJa fluorescent probe (59-FAM-CACAAGCACCTG-
CACCCTGTGCA-TAMRA-39). Lysates were separately subject-
ed to amplification of the single-copy CD8b chain gene using a
CD8b forward primer (59-CAGGACCCCAAGGACAAGTACT-
39), CD8b reverse primer (59-CACTTTCACCATACAAAA-
CTCCTTTG-39), and CD8b probe (59-FAMTGAGTTCCT-
GGCCTCCTGGAGTTCTTC-TAMRA-39). Reactions con-
tained 0.5 mM of each primer, 0.3 mM fluorescent probe, and
Platinum Quantitative PCR Supermix-UDG (Invitrogen) Ampli-
fications were performed in triplicate on an LightCycler 480 II
(Roche Diagnostics). Amplification conditions were 50uC for
2 minutes, 95uC for 5 minutes, then 40 cycles of 95uC for
15 seconds, and 60uC for 1 minute. Standards for murine TRECs
(mdREC-yJa) and CD8b were provided by Dr. Y.-W. Chu
(Center for Cancer Research, National Institutes of Health).
Standard curves were generated as described before [58]. TREC
frequency (TREC molecules per 10 000 cells) was determined by
normalizing the number of TRECs amplified in the real-time PCR
reaction to the number of amplified CD8b molecules.
Statistical analysis
Comparison between paired or unpaired groups was performed
using the appropriate Student’s t-test. A p-value,0.05 was defined
as statistically significant. All statistical analyses were performed
using the SPSS statistical software package (SPSS 19, SPSS Inc.).
Figures were created using SigmaPlot 12.0 (Systat Software Inc).
Supporting Information
Figure S1 CTLA4 and GITR expression in naı ¨ve Treg
cells. Frequency of CTLA4 (left) and GITR (right) expressing
naı ¨ve CCR7
+CD45RA
+ CD4
+CD25
highFOXP3
+ Treg cells in
healthy donors (white) and colorectal cancer patients before (light
grey) and after IL-2 administration (dark grey) before treatment.
Shown here are median, 25
th and 75
th percentile (box), 10
th and
90
th percentile (whiskers) and outliers (dots), (*, p,0.05, Student’s t
test).
(TIF)
Figure S2 Therapy schedule. Patients were first randomized
to receive CAP-1 and IL-2 with different adjuvants (dSLIM, GM-
CSF, or none). Subsequently, they were randomized to receive
their first vaccination with or without pulsed autologous dendritic
cells. Vaccinations (V) and chemotherapy (Chemo) were given in
an alternating schedule, starting with two vaccinations.
(TIF)
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